Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Hikma Pharmaceuticals Plc LSE:HIK London Ordinary Share GB00B0LCW083 ORD SHS 10P
  Price Change % Change Share Price Shares Traded Last Trade
  -38.00 -1.7% 2,199.00 177,719 15:56:16
Bid Price Offer Price High Price Low Price Open Price
2,198.00 2,200.00 2,237.00 2,191.00 2,222.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1,712.25 408.13 133.56 16.7 5,069
Last Trade Time Trade Type Trade Size Trade Price Currency
15:56:21 O 227 2,198.745 GBX

Hikma Pharmaceuticals (HIK) Latest News

More Hikma Pharmaceuticals News
Hikma Pharmaceuticals Investors    Hikma Pharmaceuticals Takeover Rumours

Hikma Pharmaceuticals (HIK) Discussions and Chat

Hikma Pharmaceuticals Forums and Chat

Date Time Title Posts
04/3/202114:15Hikma Pharmaceuticals1,165
13/1/201515:12 *** Hikma ***98

Add a New Thread

Hikma Pharmaceuticals (HIK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
15:56:222,198.752274,991.15O
15:56:152,199.0020439.80AT
15:56:132,199.00771,693.23AT
15:56:132,199.00711,561.29AT
15:56:132,199.001142,506.86AT
View all Hikma Pharmaceuticals trades in real-time

Hikma Pharmaceuticals (HIK) Top Chat Posts

DateSubject
05/3/2021
08:20
Hikma Pharmaceuticals Daily Update: Hikma Pharmaceuticals Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HIK. The last closing price for Hikma Pharmaceuticals was 2,237p.
Hikma Pharmaceuticals Plc has a 4 week average price of 2,191p and a 12 week average price of 2,191p.
The 1 year high share price is 2,766p while the 1 year low share price is currently 1,596p.
There are currently 230,495,233 shares in issue and the average daily traded volume is 833,970 shares. The market capitalisation of Hikma Pharmaceuticals Plc is £5,061,675,316.68.
26/12/2020
23:22
thewheeliedealer: Hi all, My mate Peter @Conkers3 and myself did a ‘Twin Petes Investing’ Podcast a few days before Xmas and part of our discussion includes HIK which I know C3 is keen on. We also chatted about loads of other Stocks and Ideas for research. We discussed the outlook for Markets and the most likely roadmap for the next couple of months, and as usual a fair bit of educational stuff with regards to Investing. Anyway, if you use Youtube, Apple, Audioboom, Overcast or Spotify you can find it under the 'Conkers Corner' Channel (you want Podcast TPI 38) and you can find it on Soundcloud at the link below. I hope you enjoy it and find it useful, we try to keep them light and they are totally unscripted, not like all the stuffy financial fodder you are probably more used to !! Season’s Greetings !! WD @wheeliedealer hTTps://soundcloud.com/user-479955511/conkers3-wheeliedealer-38-takeovers-vla-azn-pfe-bntx-alxn-gsk-cdm-hik-vec-av-futr
24/12/2020
07:52
johnrxx99: I'd go for the cheapest whatever, as long as it's from a recognised producer. The price never remains the same.
23/12/2020
11:58
montyhedge: Of course but what you prefer the original for the same price has a generic version. The pie big enough for everyone, GSK not going to let companies eat their lunch.
21/12/2020
11:55
montyhedge: I like Hik. All I'm saying the pie in Advair seems to me will be small for everyone, if undercutting goes on.
21/12/2020
09:45
suetballs: Well monty buy some hik to hedge your bets. I own both shares. Suet
18/12/2020
19:54
scepticalinvestor: its the same thing monty.gsk will have to cut their price by 70% to compete...
18/12/2020
16:48
montyhedge: Let's see for 2021, GSK will fight back. The genuine article for the same price or generic version. I know what I would buy.
18/12/2020
15:53
polaris: Montyhedge - are you serious? Mylan (now Viatris) launched a generic Advair in January 2019. The total GSK sales of Advair in the US are less than half of what they were in late 2018. Mylan aggressively price cut and took significant market share. The Hikma/VEC product will just exacerbate this margin cut. If you are going to make a comment, at least look at the market before punting BS. edit I'll lay it out for you, nice and simple. GSK US Advair sales: 2017 £1.61 Bn 2018 £1.097 Bn 2019 £502 M 2020 ytd £361 M GSK reduced prices in 2018, and switched patients to other products, getting ready for the generic entry. Spot the fall in sales...
18/12/2020
15:47
montyhedge: GSK will lower their price surely and blow Hikma out the water. The real thing or a generic version for the same price. Let the battle begin in 2021.
18/12/2020
08:24
robertball: I thought HIK would jump a bit higher. I guess it's got it's momentum back now.
Hikma Pharmaceuticals share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
HIK
Hikma Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210305 16:11:26